Discriminative stimulus effects of GHB and GABA(B) agonists are differentially attenuated by CGP35348.

European Journal of Pharmacology
Lawrence P CarterCharles P France

Abstract

The aim of this study was to examine the possible heterogeneity of mechanisms that contribute to the discriminative stimulus and rate-decreasing effects of gamma-hydroxybutyrate (GHB). Dose effect curves were determined for GHB and two GABA(B) receptor agonists (baclofen and SKF97541) alone and together with the selective GABA(B) receptor antagonist CGP35348 in rats discriminating GHB. In a second study, GHB and SKF97541 dose effect curves were determined alone and together with baclofen. CGP35348 attenuated the discriminative stimulus and rate-decreasing effects of SKF97541 and baclofen to a greater extent than those of GHB. In the second study, baclofen enhanced the discriminative stimulus and rate-decreasing effects of GHB and SKF97541; however, the GHB dose effect curve was not shifted in a parallel manner. Taken together, these data suggest that multiple mechanisms, possibly including GHB receptors and GABA(B) receptor subtypes, are involved in the discriminative stimulus and rate-decreasing effects of GHB.

References

Jan 1, 1989·Psychopharmacology·D V Gauvin, A M Young
Aug 15, 1984·Biochemical Pharmacology·O C Snead, C C Liu
Jan 1, 1981·Psychopharmacology·J C Winter
Jul 1, 1996·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·G AddoloratoG Gasbarrini
Feb 19, 1997·European Journal of Pharmacology·P MathivetH Bittiger
Jan 1, 1997·Journal of Geriatric Psychiatry and Neurology·M Mamelak
Mar 13, 1999·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·F Poldrugo, G Addolorato
Jun 16, 1999·Journal of Analytical Toxicology·M A ElSohly, S J Salamone
Dec 10, 1999·Neuropharmacology·K LingenhoehlJ Mosbacher
Jul 6, 2000·Southern Medical Journal·R H SchwartzM A LeBeau
Nov 2, 2001·European Journal of Pharmacology·M A CaraiG L Gessa
Oct 31, 2002·Psychopharmacology·D E McMillan, Mi Li
Feb 28, 2003·The Journal of Pharmacology and Experimental Therapeutics·Lawrence P CarterCharles P France
Sep 13, 2003·British Journal of Pharmacology·Christophe QuévaJan P Mattsson
Oct 4, 2003·Pharmacotherapy·David E Fuller, Carl S Hornfeldt
Feb 3, 2004·The British Journal of Psychiatry : the Journal of Mental Science·J RodgersA H Young
Nov 2, 2004·Journal of Analytical Toxicology·Fiona J CouperBarry K Logan
May 6, 2005·Journal of Psychopharmacology·Alejandro Gonzalez, David J Nutt

❮ Previous
Next ❯

Citations

Sep 23, 2006·Nature Clinical Practice. Neurology·Jerome M Siegel, Lisa N Boehmer
Mar 11, 2010·The Journal of Pharmacology and Experimental Therapeutics·Melanie A FelmleeMarilyn E Morris
Jul 16, 2010·The Journal of Pharmacology and Experimental Therapeutics·Wouter KoekKenner C Rice
Feb 10, 2012·The Journal of Pharmacology and Experimental Therapeutics·Wouter KoekKenner C Rice
Jan 1, 2013·The Journal of Pharmacology and Experimental Therapeutics·Wouter KoekKenner C Rice
Mar 18, 2009·The International Journal of Neuropsychopharmacology·Carmen PedrazaJosé Francisco Navarro

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.